Health+Benefits

Cigna-Express Scripts Deal Gets the Green Light

Cigna’s acquisition of Express Scripts was approved by federal officials
By Katie King Posted on September 20, 2018

Cigna’s $67 billion acquisition of pharmacy benefits manager (PBM), Express Scripts, was approved by federal officials this week.

The Council Perspective: Express Scripts is one of the last standalone PBMs. This, and other pending mergers like CVS Health and Aetna, signals a desire to lower costs and prevent any disturbance from startups and new industry players, like the recent Amazon Berkshire Hathaway JP Morgan venture. At the same time, PBMs have been criticized for their role in negotiating drug prices, leaving many questioning if mergers like this will help or hinder efforts to align incentives throughout the drug supply chain to reduce costs for end payers. To succeed, the new Cigna-Express Scripts will mostly likely need to think about its PBM arm as a value-focused component of its insurance business.

Katie King Vice President, Health Policy & Strategy, The Council Read More

More in Health+Benefits

Moving Backward on Biodefense?
Health+Benefits Moving Backward on Biodefense?
Though the Trump administration maintains it is committed to disease preparednes...
Health+Benefits Trump Administration Proposes 2026 Health and Human Services Budget
The full HHS budget for fiscal year 2026 would be more than $30 billion less tha...
The Great Good Place
Health+Benefits The Great Good Place
Q&A with Jennifer Finlay, Institute of Behavioral Science fellow, University of ...
Healthcare Providers Stay the Course on Vaccines
Health+Benefits Healthcare Providers Stay the Course on Vaccines
Q&A with Shawn Gremminger, President and CEO, National Alliance of Healthcare Pu...
ICHRAs Might Actually Be the Future
Health+Benefits ICHRAs Might Actually Be the Future
The case for employers to offer individual coverage health r...
Same Treatments, Dramatically Different Costs
Health+Benefits Same Treatments, Dramatically Different Costs
Q&A with Allison Oakes, Chief Research Officer, Trilliant He...